Curated News
By: NewsRamp Editorial Staff
May 15, 2026
Vycor Medical Q1 2026: Revenue Up 5%, Turns Operating Profit
TLDR
- Vycor Medical's VBAS revenue grew 5% with international expansion, and operating profit turned positive, signaling market advantage.
- Vycor Medical reported Q1 2026 revenue of $458,540, a 5% increase, with non-GAAP operating profit rising to $59,788 from $20,388.
- New studies show VBAS reduces neurological deficits after brain surgery, improving patient outcomes and quality of life.
- Two new peer-reviewed studies on VBAS bring total published clinical papers to 52, highlighting safer tumor resection.
Impact - Why it Matters
This news matters because Vycor Medical's financial turnaround and the positive clinical data on its ViewSite Brain Access System (VBAS) signal a growing acceptance of minimally invasive neurosurgery, which can lead to better patient outcomes with fewer complications. For investors, the company's path to profitability and international expansion suggest a strengthening business model. For patients and healthcare providers, the evidence from new studies reinforces VBAS as a safer alternative to traditional retractors, potentially reducing neurological deficits after brain surgery. Additionally, NovaVision's therapies address a critical unmet need for vision recovery after stroke, impacting millions of patients worldwide.
Summary
Vycor Medical, Inc. (OTCQB: VYCO) has announced its financial results for the first quarter ended March 31, 2026, revealing a 5% increase in total revenue to $458,540 compared to the same period in 2025. The company operates two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons, and NovaVision®, which offers therapies for visual recovery after stroke or brain injury. The Vycor Medical division saw revenue growth driven largely by international markets, a key strategic focus. Notably, the company achieved an operating profit of $45,808, a significant turnaround from an operating loss of $(12,806) in the prior year. On a non-GAAP basis, operating profit improved to $59,788 from $20,388.
The positive financial performance was bolstered by the publication of two new peer-reviewed studies on VBAS, bringing the total to 52 published clinical papers. One study highlighted the integration of neuro-navigation systems with VBAS as a paramount strategy for complex pediatric tumor resection, while a retrospective study of 23 patients demonstrated significantly fewer new neurological deficits using VBAS compared to traditional blade retractors. These findings underscore VBAS's potential for safer tumor resection. The NovaVision division, still in development, generated $18,099 in revenue with an 89% gross margin. The company also reported non-GAAP cash operating expenses of $315,365, down from $338,146, contributing to improved profitability.
Vycor Medical's GAAP net loss available to common stockholders narrowed to $(142,077), or $(0.00) per share, from $(200,748) in the prior year. Non-GAAP net loss was $(128,097). The company continues to invest in its innovative portfolio, including VBAS, protected by 49 issued patents, and NovaVision's Visual Restoration Therapy, the only FDA-cleared therapy for vision rehabilitation after neurological damage. With over 350 US hospitals using VBAS and a growing international presence, Vycor is positioning itself as a leader in minimally invasive neurosurgical and vision rehabilitation solutions. For more details, view the original release on NEWMEDIAWIRE.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Vycor Medical Q1 2026: Revenue Up 5%, Turns Operating Profit
